文献速递前列腺癌

基于多参数磁共振成像的高级别前列腺癌预测:改进Rotterdam ERSPC风险计算器

Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
PubMed 文献 · Eur Urol · 2018-08-03

研究在961例接受mpMRI及12针TRUS-Bx±MRI-TBx的男性中,将PI-RADS评分和年龄加入ERSPC-RC3和ERSPC-RC4,构建MRI-ERSPC-RCs。MRI-ERSPC-RC3和MRI-ERSPC-RC4预测高级别前列腺癌的AUC分别显著高于原版(0.84 vs 0.76;0.85 vs 0.74)。对于已活检男性,MRI-ERSPC-RC4在≥10%风险阈值下可避免36%活检,漏诊4%高级别癌。

要点

  • MRI-ERSPC-RC3预测高级别前列腺癌AUC 0.84,高于原版0.76。
  • MRI-ERSPC-RC4预测高级别前列腺癌AUC 0.85,高于原版0.74。
  • 已活检男性用MRI-ERSPC-RC4≥10%阈值可避免36%活检,漏诊4%高级别癌。

核心结论

  • 将PI-RADS评分和年龄加入ERSPC-RC3和ERSPC-RC4可提高对高级别前列腺癌的预测区分度。
  • MRI-ERSPC-RC3用于初诊活检男性避免活检的价值仍存疑。
  • MRI-ERSPC-RC4用于已活检男性在本队列中可避免36%活检,漏诊4%高级别癌。

研究设计与样本

  • 多中心研究,共961例男性接受mpMRI和12针TRUS-Bx±MRI-TBx(PI-RADS≥3时加做MRI-TBx)。
  • 504例初诊活检男性用于调整ERSPC-RC3,457例已活检男性用于调整ERSPC-RC4。
  • 采用逻辑回归模型构建MRI-ERSPC-RCs,比较原版与新版AUC,并进行决策曲线分析。

主要发现

  • MRI-ERSPC-RC3预测高级别前列腺癌AUC 0.84(95%CI 0.81-0.88),原版ERSPC-RC3为0.76(95%CI 0.71-0.80),p<0.01。
  • MRI-ERSPC-RC4预测高级别前列腺癌AUC 0.85(95%CI 0.81-0.89),原版ERSPC-RC4为0.74(95%CI 0.69-0.79),p<0.01。
  • 决策曲线分析显示MRI-ERSPC-RC4在高级别前列腺癌风险阈值≥5%时有明确净获益,MRI-ERSPC-RC3则无。
  • MRI-ERSPC-RC4采用≥10%高级别前列腺癌风险阈值活检时,避免36%活检,未活检男性中低级别和高级别前列腺癌漏诊率分别为15%和4%。

关键数值与推荐

  • MRI-ERSPC-RC3预测高级别前列腺癌AUC 0.84(95%CI 0.81-0.88),原版0.76(95%CI 0.71-0.80),p<0.01。
  • MRI-ERSPC-RC4预测高级别前列腺癌AUC 0.85(95%CI 0.81-0.89),原版0.74(95%CI 0.69-0.79),p<0.01。
  • MRI-ERSPC-RC4在高级别前列腺癌风险阈值≥5%时决策曲线分析显示净获益。
  • MRI-ERSPC-RC4采用≥10%高级别前列腺癌风险阈值活检可避免36%活检,漏诊高级别癌4%。

临床怎么用

  • 对于已活检男性,可考虑使用MRI-ERSPC-RC4结合PI-RADS评分和年龄评估高级别前列腺癌风险。
  • 在MRI-ERSPC-RC4评估后,采用≥10%高级别前列腺癌风险阈值决定是否活检可能减少不必要的活检。
  • 初诊活检男性使用MRI-ERSPC-RC3避免活检的价值尚不明确,需谨慎应用。

局限性

  • 研究未明确报告样本量以外的其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Rotterdam European Randomized Study of Screening for Prostate Cancer risk calculators (ERSPC-RCs) help to avoid unnecessary transrectal ultrasound-guided systematic biopsies (TRUS-Bx). Multivariable risk stratification could also avoid unnecessary biopsies following multiparametric magnetic resonance imaging (mpMRI). OBJECTIVE: To construct MRI-ERSPC-RCs for the prediction of any- and high-grade (Gleason score ≥3 + 4) prostate cancer (PCa) in 12-core TRUS-Bx±MRI-targeted biopsy (MRI-TBx) by adding Prostate Imaging Reporting and Data System (PI-RADS) and age as parameters to the ERSPC-RC3 (biopsy-naïve men) and ERSPC-RC4 (previously biopsied men). DESIGN, SETTING, AND PARTICIPANTS: A total of 961 men received mpMRI and 12-core TRUS-Bx±MRI-TBx (in case of PI-RADS ≥3) in five institutions. Data of 504 biopsy-naïve and 457 previously biopsied men were used to adjust the ERSPC-RC3 and ERSPC-RC4. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Logistic regression models were constructed. The areas under the curve (AUCs) of the original ERSPC-RCs and MRI-ERSPC-RCs (including PI-RADS and age) for any- and high-grade PCa were compared. Decision curve analysis was performed to assess the clinical utility of the MRI-ERSPC-RCs. RESULTS AND LIMITATIONS: MRI-ERSPC-RC3 had a significantly higher AUC for high-grade PCa compared with the ERSPC-RC3: 0.84 (95% confidence interval [CI] 0.81-0.88) versus 0.76 (95% CI 0.71-0.80, p<0.01). Similarly, MRI-ERSPC-RC4 had a higher AUC for high-grade PCa compared with the ERSPC-RC4: 0.85 (95% CI 0.81-0.89) versus 0.74 (95% CI 0.69-0.79, p<0.01). Unlike for the MRI-ERSPC-RC3, decision curve analysis showed clear net benefit of the MRI-ERSPC-RC4 at a high-grade PCa risk threshold of ≥5%. Using a ≥10% high-grade PCa risk threshold to biopsy for the MRI-ERSPC-RC4, 36% biopsies are saved, missing low- and high-grade PCa, respectively, in 15% and 4% of men who are not biopsied. CONCLUSIONS: We adjusted the ERSPC-RCs for the prediction of any- and high-grade PCa in 12-core TRUS-Bx±MRI-TBx. Although the ability of the MRI-ERSPC-RC3 for biopsy-naïve men to avoid biopsies remains questionable, application of the MRI-ERSPC-RC4 in previously biopsied men in our cohort would have avoided 36% of biopsies, missing high-grade PCa in 4% of men who would not have received a biopsy. PATIENT SUMMARY: We have constructed magnetic resonance imaging-based Rotterdam European Randomized study of Screening for Prostate Cancer (MRI-ERSPC) risk calculators for prostate cancer prediction in transrectal ultrasound-guided biopsy and MRI-targeted biopsy by incorporating age and Prostate Imaging Reporting and Data System score into the original ERSPC risk calculators. The MRI-ERSPC risk calculator for previously biopsied men could be used to avoid one-third of biopsies following MRI.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Alberts AR, Roobol MJ, Verbeek JFM, et al. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. Eur Urol. 2018. PMID: 30082150. doi:10.1016/j.eururo.2018.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。